These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27913052)

  • 21. Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.
    Ericson KJ; Wu SS; Lundy SD; Thomas LJ; Klein EA; McKenney JK
    J Urol; 2020 Feb; 203(2):311-319. PubMed ID: 31483693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
    Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
    Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
    Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.
    Faraj SF; Albadine R; Chaux A; Gonzalez-Roibon N; Hicks J; Humphreys E; Partin A; Netto GJ
    Urology; 2013 Nov; 82(5):1083-9. PubMed ID: 24035134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
    Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
    Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
    J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
    Ronen S; Abbott DW; Kravtsov O; Abdelkader A; Xu Y; Banerjee A; Iczkowski KA
    Hum Pathol; 2017 Jul; 65():85-91. PubMed ID: 28504208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
    Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis.
    Sathyanarayana UG; Birch C; Nagle RB; Tomlins SA; Palanisamy N; Zhang W; Hubbard A; Brunhoeber P; Wang Y; Tang L
    Appl Immunohistochem Mol Morphol; 2015; 23(5):364-73. PubMed ID: 25265431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
    Warrick JI; Humphrey PA
    Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
    Ormond DR; Kleinschmidt-DeMasters BK; Cavalcante D; Smith EE; Cramer SD; Lucia MS
    J Neurooncol; 2019 Apr; 142(2):319-325. PubMed ID: 30656528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
    Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERG oncoprotein expression in prostatic acinar adenocarcinoma; clinicopathologic significance.
    Hashmi AA; Khan EY; Irfan M; Ali R; Asif H; Naeem M; Nisar L; Faridi N; Khan A; Edhi MM
    BMC Res Notes; 2019 Jan; 12(1):35. PubMed ID: 30658688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
    Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
    Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
    Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.
    Kimura T; Furusato B; Miki J; Yamamoto T; Hayashi N; Takahashi H; Kamata Y; van Leenders GJ; Visakorpi T; Egawa S
    Pathol Int; 2012 Nov; 62(11):742-8. PubMed ID: 23121605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR.
    Simper NB; Jones CL; MacLennan GT; Montironi R; Williamson SR; Osunkoya AO; Wang M; Zhang S; Grignon DJ; Eble JN; Tran T; Wang L; Baldrige LA; Cheng L
    Hum Pathol; 2015 Jun; 46(6):805-12. PubMed ID: 25870120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.